Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids
Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data on its obesity drug Liraglutide, which has ... Read More
Shockwave through biotech: AN2 Therapeutics slashes workforce after trial fails
AN2 Therapeutics, Inc., a pioneering force in novel small molecule drugs, has announced a dramatic reduction of its workforce by approximately 50%. This decision follows ... Read More
Is the cure for PTSD waiting in the wings? FDA says not yet!
In a significant regulatory decision, the U.S. Food and Drug Administration (FDA) has decided not to approve the use of MDMA, commonly known as ecstasy, ... Read More
HCLTech launches advanced clinical trials solution with Denodo and AWS
HCLTech, a prominent global technology company, has unveiled a cutting-edge clinical trials and diagnosis solution developed in collaboration with Denodo, a leader in data management, ... Read More
FDA committee endorses Zevra Therapeutics’ arimoclomol as a treatment for Niemann-Pick Disease Type C
In a notable advancement for rare disease treatment, Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has received a significant endorsement from the U.S. Food and Drug Administration ... Read More
$35 million boost for Rona Therapeutics: A new era in RNA medicine begins!
Rona Therapeutics, a clinical-stage company leading the way in nucleic acid drug research and development, has successfully completed a Series A+ financing round, raising $35 ... Read More
Exscientia takes full ownership of cdk7 inhibitor in oncology breakthrough
Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full ownership of the oral CDK7 inhibitor program ... Read More
Sermonix Pharmaceuticals awarded U.S. patent for lasofoxifene in breast cancer treatment
Sermonix Pharmaceuticals Inc., a leader in biopharmaceutical innovations, has achieved a significant milestone with the issuance of a new U.S. patent that broadens the application ... Read More
Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial. The ... Read More
Soligenix announces promising results in extended HyBryte treatment study for cutaneous T-cell lymphoma
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, has shared an interim update on a key study involving extended HyBryte treatment in patients with early-stage ... Read More